Skip to main content
Equibles
PRAX logo

PRAX · Praxis Precision Medicines, Inc. · Metrics

Track PRAX — free

Use PRAX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PRAX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$264.49 +4.32 (+1.66%) At close · Oct 20
Russell 2000 member Rebalance outlook locked
Market Cap
$7.26B
Shares
27.92M
Volume · Oct 20 886.06K Avg daily vol (3M) 451.59K

PRAX metrics

63 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$264.49
Market cap
$7.26B

Price action

20 metrics
Price change (1W)
+3.5%
Price change (30D)
-12.9%
Price change (3M)
-14.5%
Price change (6M)
-24.1%
Price change (YTD)
-11.7%
Price change (1Y)
+36.9%
Trailing year
Price change (5Y)
—
52-week high
$386.33
52-week low
$164.09
Change from 52-week high
-32.7%
Change from 52-week low
+58.6%
Annualized volatility
73.9%
Annualized volatility (3M)
58.0%
Beta
1.3
RSI (14D)
39.7
Price vs SMA 50
-18.7%
Price vs SMA 200
-17.5%
Avg volume (3M)
441,549
Relative volume
2.0
Average dollar volume
$138.33M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
27.92M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
5.0
reciprocal yield 19.9%
FCF yield
-4.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-5.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
313.5×
reciprocal yield 0.3%
EV / revenue historical average (5Y)
313.5×
reciprocal yield 0.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$378.17M
Net income (TTM)
−$339.13M
Trailing 12 months
Diluted EPS (TTM)
$-12.95
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.37
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$34.85

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+35.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-25.3%
Return on assets
-24.4%
Debt / equity
0.0
Current ratio
15.7
EBITDA (TTM)
—
Free cash flow (TTM)
−$305.38M
Quick ratio
15.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$758.55M
Latest balance sheet
Cash & equivalents
$474.76M
Total assets
$1.39B
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$305.08M
Capital expenditures (TTM)
$307,000
R&D (TTM)
$290.71M
SG&A (TTM)
—
Stock compensation (TTM)
$45.81M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
316
13F filer change QoQ
+14
Institutional ownership
124.4%
Conviction holders (share of 13F filers)
5.8%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+6.0%
Holder tenure
9.7
Price vs estimated holder cost
+104.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
18.7%

Short interest

3 metrics
Short interest
15.0%
Latest settlement · 7.2 days to cover
Days to cover
7.2d
Short-squeeze score
75 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1689548 CUSIP 74006W207 13F (30d) 18 filings 18 filers Visit website Investor relations